Acute Coronary Syndromes in Patients with Chronic Kidney Disease
The DOI matches its Crossref record.
Abstract
Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. The available data suggest that efforts to reduce mortality in the CKD population should be focused on treatment and prevention of, among others, coronary artery disease and congestive heart failure. Accelerated atherosclerosis present in CKD patients also leads to a decline in renal function. Definite data concerning the treatment of heart failure in CKD patients are lacking, because patients with significant renal impairment have mostly been excluded from randomized studies. Nevertheless, it seems that CKD patients should receive similar cardiovascular treatment to that used in patients with normal kidney function, but the doses of drugs ought to be titrated to achieve an optimal effect while avoiding adverse events. Several studies have also shown that despite the high risk, in patients with acute coronary syndrome (ACS), revascularization procedures in patients with CKD appear to be advantageous in the long run and are therefore justified. However, large clinical trials are needed to confirm the benefits and to identify possible disadvantages associated with various methods of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cholesterol lowering with statins reduces the incidence of HF in patients with CAD (stable CAD or a history of ACS) without previous HF; this has been shown consistently in RCTs that have compared statin vs. no statin treatment [463,464] as well as more-intensive vs. lessintensive statin therapy [465-468].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [468]
In the citing paper
“In the adult population, a decreasing GFR is associated with an increased CVD risk, independent of other CV risk factors. 388-391”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [389]
In the citing paper
“Patients with stage 3-5 CKD have to be considered at high or very high CV risk.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [389]
Citations
Cites
Still being checked.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“In the adult population, decreasing GFR is associated with increased CVD risk, independent of other CV risk factors.(489) 492 There is an increased risk of both atherosclerotic vascular disease and structural heart disease.”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Disorders of lipid metabolism. Clinical Guidelines 2023
Ezhov, M. V., Kukharchuk, V. V., Sergienko, I. V., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Aronov, D. M., Arutyunov, G. P., Akhmedzhanov, N. M., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 219
Metadata
- Authors
- Franczyk-Skóra, B., Gluba, A., Banach, M., Rozentryt, P., Poloński, L., & Rysz, J.
- Affiliations
- Medical University of Lodz (PL)
- Corresponding author
- Rysz, Jacek
- Venue
- Current Vascular Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-08-31
- Volume
- 11
- Issue
- 5
- Pages
- 758-767
- ISSN
- 1570-1611 (ISSN-L)
- OpenAlex
- W2102376018
- Cited by
- 23
- References
- 0
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 1 · 2019: 7 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 2 · 2013: 2
- FWCI
- 2.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Vascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- acute coronary syndrome, chronic kidney disease, cardiovascular risk, coronary artery disease, congestive heart failure, premature atherosclerosis, renal dysfunction, revascularization, mortality
- MeSH terms
- Humans, Renal Insufficiency, Chronic, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute Coronary Syndromes in Patients with Chronic Kidney Disease. https://app.cochat.ai/papers/10.2174/1570161111311050013
- The paper
- Franczyk-Skóra, B., Gluba, A., Banach, M., Rozentryt, P., Poloński, L., & Rysz, J. (2013). Acute Coronary Syndromes in Patients with Chronic Kidney Disease. Current Vascular Pharmacology. https://doi.org/10.2174/1570161111311050013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.